Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | AGXT | P21549 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1862187 | 0.85 | MAPT (0.36) | MEN1KMT2AMAPTALDH1A1IDO1 | |
| SCHEMBL1859756 | 0.85 | IDO1 (0.34) | MEN1KMT2AMAPTALDH1A1IDO1 | |
| SCHEMBL1857795 | 0.84 | CTRC (0.44) | MEN1KMT2AALDH1A1CYP3A4HPGD | |
| SCHEMBL1859772 | 0.80 | LTA4H (0.46) | MAPTALDH1A1IDO1HPGDALOX15 | |
| SCHEMBL1859749 | 0.72 | TAAR1 (0.37) | KMT2AMAPTALDH1A1TAAR1HPGD | |
| SCHEMBL1860328 | 0.70 | CTRC (0.39) | — | |
| SCHEMBL1106684 | 0.69 | IDO1 (0.58) | MEN1KMT2AMAPTALDH1A1IDO1 | |
| SCHEMBL11722438 | 0.68 | IDO1 (0.56) | MEN1KMT2AMAPTALDH1A1IDO1 | |
| SCHEMBL5467702 | 0.68 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1IDO1TAAR1 | |
| SCHEMBL1861219 | 0.67 | IDO1 (0.43) | KMT2AALDH1A1IDO1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683074-B2 | 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | BIOTIE THERAPIES GMBH (DE) | 2010-03-23 | — | — | US | disclosed |
| US-7419987-B2 | 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | ELBION AG (DE) | 2008-09-02 | — | — | US | disclosed |
| US-20080207680-A1 | 7-Azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | BIOTIE THERAPIES GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-7169787-B2 | 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | ELBION AG (DE) | 2007-01-30 | — | — | US | disclosed |
| US-20060258700-A1 | 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | BIOTIE THERAPIES GMBH (DE) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258700-A1 | 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | PDE4A, PDE4B, PDE3A | MEN1 1903/4885KMT2A 1003/4885MAPT 4493/4885 |
| US-20080207680-A1 | 7-Azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | PDE4A, PDE4B, PDE7A | MEN1 2289/4885KMT2A 1119/4885MAPT 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.